EQUIPMENT
– gÉNomiCS
& TRANSCRIPTOMICS
NextSeq550 NGS sequencing
The platform has an Illumina NextSeq 550 (www.illumina.com) which generates up to 400 million single-end reads/run High output or 130 million single-end reads/run Mid output.
The main application is the analysis of the coding transcriptome (RNA-Seq) after polyA or total selection by ribosomal depletion or in single cells.
The instrument also has the capacity to handle small RNA sequencing (miRNAs), amplicon or panel, exome and ChIP (chromatin immunoprecipitation) projects. The implementation of protocols for these applications is done according to the requests and specifications of each project.
Access to this technology is by project service and specific quote.
Sequencing recommendations:
|
Research |
Measures |
Size and quantity of reads/sample |
Number of samples/run |
||
|
Mid output 130Mreads |
High output 400Mreads |
||||
|
mRNA-Seq |
Transcriptome Coding |
2X75pb |
25 M |
4 |
16 |
|
Total RNA seq |
Transcriptome Coding and non-Coding |
2X75pb |
50 M |
2 |
8 |
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
CRCT-Oncopole Follow 1,433 1,279
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
;
🇬🇧Cytidine deaminase-dependent mitochondrial biogenesis as a potential vulnerability in pancreatic cancer cells. ImPact team @CordelierPierre article from @crctoncopole published in @CommsBio
➡️https://www.crct-inserm.fr/en/targeting-the-energy-production-process-in-pancreatic-cancer-cells-which-relies-on-an-enzyme-called-cytidine-deaminase-could-make-these-cells-more-vulnerable/
Nous contacter
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?
